AtriCure, Inc. (ATRC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATRC POWR Grades
- ATRC scores best on the Stability dimension, with a Stability rank ahead of 57.62% of US stocks.
- The strongest trend for ATRC is in Growth, which has been heading up over the past 179 days.
- ATRC ranks lowest in Momentum; there it ranks in the 19th percentile.
ATRC Stock Summary
- With a price/earnings ratio of 59.23, AtriCure Inc P/E ratio is greater than that of about 87.72% of stocks in our set with positive earnings.
- With a price/sales ratio of 10.84, AtriCure Inc has a higher such ratio than 86.43% of stocks in our set.
- In terms of twelve month growth in earnings before interest and taxes, AtriCure Inc is reporting a growth rate of -228.15%; that's higher than merely 8.58% of US stocks.
- Stocks that are quantitatively similar to ATRC, based on their financial statements, market capitalization, and price volatility, are DHX, XENT, FLNT, TRUE, and JMIA.
- ATRC's SEC filings can be seen here. And to visit AtriCure Inc's official web site, go to www.atricure.com.
ATRC Valuation Summary
- ATRC's price/sales ratio is 13.9; this is 22.47% higher than that of the median Healthcare stock.
- Over the past 196 months, ATRC's price/sales ratio has gone down 2.2.
- Over the past 196 months, ATRC's price/sales ratio has gone down 2.2.
Below are key valuation metrics over time for ATRC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ATRC | 2021-08-31 | 13.9 | 8.8 | -59.6 | -65.5 |
| ATRC | 2021-08-30 | 13.9 | 8.8 | -59.8 | -65.7 |
| ATRC | 2021-08-27 | 14.1 | 8.9 | -60.3 | -66.3 |
| ATRC | 2021-08-26 | 13.7 | 8.6 | -58.7 | -64.6 |
| ATRC | 2021-08-25 | 14.0 | 8.8 | -60.0 | -65.9 |
| ATRC | 2021-08-24 | 14.3 | 9.0 | -61.5 | -67.5 |
ATRC Growth Metrics
- Its 5 year price growth rate is now at 171.19%.
- Its 5 year net income to common stockholders growth rate is now at -45.14%.
- Its 5 year net cashflow from operations growth rate is now at -88.31%.
The table below shows ATRC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 274.329 | -13.78 | 50.199 |
| 2021-09-30 | 258.836 | -10.127 | 45.378 |
| 2021-06-30 | 243.133 | -6.083 | -56.679 |
| 2021-03-31 | 212.581 | -13.098 | -48.664 |
| 2020-12-31 | 206.531 | -19.869 | -48.155 |
| 2020-09-30 | 210.127 | -27.352 | -45.689 |
ATRC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ATRC has a Quality Grade of C, ranking ahead of 28.8% of graded US stocks.
- ATRC's asset turnover comes in at 0.344 -- ranking 124th of 186 Medical Equipment stocks.
- INGN, BSX, and GKOS are the stocks whose asset turnover ratios are most correlated with ATRC.
The table below shows ATRC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.344 | 0.746 | -0.169 |
| 2021-03-31 | 0.301 | 0.729 | -0.142 |
| 2020-12-31 | 0.311 | 0.723 | -0.152 |
| 2020-09-30 | 0.337 | 0.722 | -0.163 |
| 2020-06-30 | 0.361 | 0.722 | -0.213 |
| 2020-03-31 | 0.463 | 0.736 | -0.227 |
ATRC Price Target
For more insight on analysts targets of ATRC, see our ATRC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $96.71 | Average Broker Recommendation | 1.31 (Strong Buy) |
ATRC Stock Price Chart Interactive Chart >
ATRC Price/Volume Stats
| Current price | $41.01 | 52-week high | $89.18 |
| Prev. close | $40.86 | 52-week low | $32.83 |
| Day low | $40.07 | Volume | 276,300 |
| Day high | $41.77 | Avg. volume | 272,866 |
| 50-day MA | $43.76 | Dividend yield | N/A |
| 200-day MA | $62.24 | Market Cap | 1.90B |
AtriCure, Inc. (ATRC) Company Bio
Atricure provides atrial fibrillation solutions worldwide. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The company was founded in 2000 and is based in West Chester, Ohio.
Latest ATRC News From Around the Web
Below are the latest news stories about AtriCure Inc that investors may wish to consider to help them evaluate ATRC as an investment opportunity.
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility... |
AtriCure Inc. (ATRC) CEO Michael Carrel on Q4 2021 Results - Earnings Call TranscriptAtriCure Inc. (ATRC) Q4 2021 Results Conference Call February 15, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants David Saxon - Needham Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler Bill Plovanic - Canaccord... |
Atricure (ATRC) Gets a Buy Rating from NeedhamNeedham analyst Michael Matson reiterated a Buy rating on Atricure (ATRC – Research Report) today and set a price target of $79.00. The company's shares closed last Tuesday at $65.50. According to TipRanks.com, Matson is a 4-star analyst with an average return of 6.6% and a 49.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings. Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $93.67, representing a 43.8% upside. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $94.00 price target. |
AtriCure Reports Deeper Losses In Q4 Despite 27% Jump In Sales, Issues FY22 GuidanceAtriCure Inc (NASDAQ: ATRC ) reported Q4 FY21 sales of $73.2 million , an increase of 26.8% Y/Y (+27.4% on a constant currency basis), beating the consensus of $72.65 million. U.S. revenue was $61.2 million, increasing 29.1% reflected strong growth across all product lines, driven by sales of cryoSPHERE, EPi-Sense, and AtriClip Flex⋅V products. International revenue increased 16.3% (+19.3% on a constant currency basis) to … Full story available on Benzinga.com |
Wall Street Analysts Think AtriCure (ATRC) Could Surge 52%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
ATRC Price Returns
| 1-mo | -2.47% |
| 3-mo | -35.38% |
| 6-mo | -36.84% |
| 1-year | -49.43% |
| 3-year | 30.56% |
| 5-year | 70.38% |
| YTD | -41.02% |
| 2021 | 24.90% |
| 2020 | 71.24% |
| 2019 | 6.24% |
| 2018 | 67.76% |
| 2017 | -6.80% |
Continue Researching ATRC
Here are a few links from around the web to help you further your research on AtriCure Inc's stock as an investment opportunity:AtriCure Inc (ATRC) Stock Price | Nasdaq
AtriCure Inc (ATRC) Stock Quote, History and News - Yahoo Finance
AtriCure Inc (ATRC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...